help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nichols, M.
Right arrow Articles by Stewart, A. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nichols, M.
Right arrow Articles by Stewart, A. F.
Molecular Endocrinology 11 (7): 950-961
Copyright © 1997 by The Endocrine Society

FLP Recombinase/Estrogen Receptor Fusion Proteins Require the Receptor D Domain for Responsiveness to Antagonists, but not Agonists

Mark Nichols, Jeanette M. J. Rientjes, Colin Logie and A. Francis Stewart

European Molecular Biology Laboratory, Gene Expression Program, D-69117 Heidelberg, Germany

The ligand-binding domains of steroid receptors convey ligand-dependent regulation to certain proteins to which they are fused. Here we characterize fusion proteins between a site-specific recombinase, FLP, and steroid receptor ligand-binding domains. These proteins convert ligand binding into DNA recombination. Thus, ligand binding is directly coupled to an enzyme activity that is easily measured by DNA rearrangements or heritable genetic changes in marker gene expression, as opposed to the multiple events leading to transcription. Recombination by a FLP-estrogen receptor (FLP-EBD) fusion is activated by all tested estrogens, whether agonists or antagonists, indicating that all induce EBD release from the 90-kDa heat shock protein complex. Altering the distance between FLP and the EBD domain in the fusion proteins, by reducing the included length of the estrogen receptor D domain, affects ligand efficacy. A FLP-EBD with no D domain shows reduced inducibility by agonists and, unexpectedly, complete insensitivity to induction by all antagonists tested. A FLP-EBD including some D domain shows a ligand-inducible phenotype intermediate to those displayed by FLP-EBDs containing all or none of the D domain. Thus, we observed a tethered interference between FLP and the EBD domains that differs depending on the distance between the two domains, the conformations induced by agonists or antagonists, and which presents a previously undetectable distinction between estrogen agonists and antagonists in yeast.




This article has been cited by other articles:


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Koide, S. Abbatiello, L. Rothgery, and S. Koide
Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor
PNAS, January 24, 2002; (2002) 32665299.
[Abstract] [Full Text] [PDF]


Home page
Nucleic Acids ResHome page
T.-H. Cheng, C.-R. Chang, P. Joy, S. Yablok, and M. R. Gartenberg
Controlling gene expression in yeast by inducible site-specific recombination
Nucleic Acids Res., December 15, 2000; 28(24): e108 - e108.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
D. Rinaudo, S. Lamartina, G. Roscilli, G. Ciliberto, and C. Toniatti
Conditional Site-Specific Integration into Human Chromosome 19 by Using a Ligand-Dependent Chimeric Adeno-Associated Virus/Rep Protein
J. Virol., January 1, 2000; 74(1): 281 - 294.
[Abstract] [Full Text]


Home page
DevelopmentHome page
K Weigmann and S. Cohen
Lineage-tracing cells born in different domains along the PD axis of the developing Drosophila leg
Development, January 9, 1999; 126(17): 3823 - 3830.
[Abstract] [PDF]


Home page
EndocrinologyHome page
G. G. J. M. Kuiper, J. G. Lemmen, B. Carlsson, J. C. Corton, S. H. Safe, P. T. van der Saag, B. van der Burg, and J.-A. Gustafsson
Interaction of Estrogenic Chemicals and Phytoestrogens with Estrogen Receptor {beta}
Endocrinology, October 1, 1998; 139(10): 4252 - 4263.
[Abstract] [Full Text] [PDF]


Home page
Mol. Endocrinol.Home page
C. Logie, M. Nichols, K. Myles, J. W. Funder, and A. F. Stewart
Positive and Negative Discrimination of Estrogen Receptor Agonists and Antagonists Using Site-Specific DNA Recombinase Fusion Proteins
Mol. Endocrinol., August 1, 1998; 12(8): 1120 - 1132.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. Koide, S. Abbatiello, L. Rothgery, and S. Koide
Probing protein conformational changes in living cells by using designer binding proteins: Application to the estrogen receptor
PNAS, February 5, 2002; 99(3): 1253 - 1258.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1997 by The Endocrine Society